Bernardo H.L. Goulart, MD, on Stage IV NSCLC: High Drug Costs May Affect Survival
2019 Quality Care Symposium
Bernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive non–small cell lung cancer (Abstract 3).
Ryan Huey, MD, of The University of Texas MD Anderson Cancer Center, discusses his findings that showed the large financial burden on lower-income patients enrolled in phase I trials (Abstract 8).
Linda D. Bosserman, MD, of City of Hope, discusses guidelines vs pathways, how to personalize pathways, integrated diagnostics, supportive care regimens, and financial guidance for patients with cancer.
Cary P. Gross, MD, of Yale School of Medicine, discusses the challenges of implementing pathways and guiding patient decision-making on treatment.
Matthew B. Schabath, PhD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the disparities in cancer care among members of the LGBTQ community and the need to collect more data in order to close that gap.
Karen M. Winkfield, MD, PhD, of the Wake Forest Baptist Medical Center, discusses cultural factors that contribute to cancer care disparities, the role of national policy in addressing inequities in access to care, and what local institutions can do to improve the situation.